Exact Mass: 632.3574

Calenduloside E

C36H56O9 (632.3924)

Oleanolic acid 3-O-beta-D-glucosiduronic acid is a beta-D-glucosiduronic acid. It is functionally related to an oleanolic acid. Calenduloside E is a natural product found in Anredera baselloides, Polyscias scutellaria, and other organisms with data available. See also: Calendula Officinalis Flower (part of). Constituent of Calendula officinalis (pot marigold), Beta vulgaris (sugar beet) and Momordica cochinchinensis (Chinese cucumber). Oleanolic acid 3-glucuronide is found in common beet, green vegetables, and root vegetables. Calenduloside E is found in common beet. Calenduloside E is a constituent of Calendula officinalis (pot marigold), Beta vulgaris (sugar beet) and Momordica cochinchinensis (Chinese cucumber). Calenduloside E (CE) is a natural pentacyclic triterpenoid saponin extracted from Aralia elata. Calenduloside E (CE) has anti-apoptotic potent by targeting heat shock protein 90 (Hsp90)[1]. Calenduloside E (CE) is a natural pentacyclic triterpenoid saponin extracted from Aralia elata. Calenduloside E (CE) has anti-apoptotic potent by targeting heat shock protein 90 (Hsp90)[1].

Geissospermine

C40H48N4O3 (632.3726)

A indole alkaloid comprising two indole-derived polycyclic moieties joined by a cyclic ether linkage.

Coagulin R 3-glucoside

C34H48O11 (632.3196)

Coagulin R 3-glucoside is found in fruits. Coagulin R 3-glucoside is a constituent of Physalis peruviana (Cape gooseberry). Constituent of Physalis peruviana (Cape gooseberry). Coagulin R 3-glucoside is found in fruits.

Cloversaponin I

C36H56O9 (632.3924)

Constituent of Trifolium repens (white clover). Cloversaponin I is found in tea, herbs and spices, and green vegetables. Cloversaponin I is found in green vegetables. Cloversaponin I is a constituent of Trifolium repens (white clover).

Lucyoside K

C36H56O9 (632.3924)

Lucyoside K is found in fruits. Lucyoside K is a constituent of Luffa cylindrica (smooth luffa). Constituent of Luffa cylindrica (smooth luffa). Lucyoside K is found in fruits.

Metabolite B

C36H56O9 (632.3924)

PA(12:0/18:1(12Z)-O(9S,10R))

C33H61O9P (632.4053)

PA(12:0/18:1(12Z)-O(9S,10R)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(12:0/18:1(12Z)-O(9S,10R)), in particular, consists of one chain of one dodecanoyl at the C-1 position and one chain of 9,10-epoxy-octadecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(18:1(12Z)-O(9S,10R)/12:0)

C33H61O9P (632.4053)

PA(18:1(12Z)-O(9S,10R)/12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:1(12Z)-O(9S,10R)/12:0), in particular, consists of one chain of one 9,10-epoxy-octadecenoyl at the C-1 position and one chain of dodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(12:0/18:1(9Z)-O(12,13))

C33H61O9P (632.4053)

PA(12:0/18:1(9Z)-O(12,13)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(12:0/18:1(9Z)-O(12,13)), in particular, consists of one chain of one dodecanoyl at the C-1 position and one chain of 12,13-epoxy-octadecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(18:1(9Z)-O(12,13)/12:0)

C33H61O9P (632.4053)

PA(18:1(9Z)-O(12,13)/12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:1(9Z)-O(12,13)/12:0), in particular, consists of one chain of one 12,13-epoxy-octadecenoyl at the C-1 position and one chain of dodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(8:0/PGE2)

C31H53O11P (632.3325)

PA(8:0/PGE2) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(8:0/PGE2), in particular, consists of one chain of one octanoyl at the C-1 position and one chain of Prostaglandin E2 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(PGE2/8:0)

C31H53O11P (632.3325)

PA(PGE2/8:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(PGE2/8:0), in particular, consists of one chain of one Prostaglandin E2 at the C-1 position and one chain of octanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(8:0/PGD2)

C31H53O11P (632.3325)

PA(8:0/PGD2) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(8:0/PGD2), in particular, consists of one chain of one octanoyl at the C-1 position and one chain of Prostaglandin D2 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(PGD2/8:0)

C31H53O11P (632.3325)

PA(PGD2/8:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(PGD2/8:0), in particular, consists of one chain of one Prostaglandin D2 at the C-1 position and one chain of octanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(8:0/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S))

C31H53O11P (632.3325)

PA(8:0/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(8:0/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)), in particular, consists of one chain of one octanoyl at the C-1 position and one chain of Lipoxin A4 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/8:0)

C31H53O11P (632.3325)

PA(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/8:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/8:0), in particular, consists of one chain of one Lipoxin A4 at the C-1 position and one chain of octanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(i-12:0/18:1(12Z)-O(9S,10R))

C33H61O9P (632.4053)

PA(i-12:0/18:1(12Z)-O(9S,10R)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-12:0/18:1(12Z)-O(9S,10R)), in particular, consists of one chain of one 10-methylundecanoyl at the C-1 position and one chain of 9,10-epoxy-octadecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(18:1(12Z)-O(9S,10R)/i-12:0)

C33H61O9P (632.4053)

PA(18:1(12Z)-O(9S,10R)/i-12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:1(12Z)-O(9S,10R)/i-12:0), in particular, consists of one chain of one 9,10-epoxy-octadecenoyl at the C-1 position and one chain of 10-methylundecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(i-12:0/18:1(9Z)-O(12,13))

C33H61O9P (632.4053)

PA(i-12:0/18:1(9Z)-O(12,13)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-12:0/18:1(9Z)-O(12,13)), in particular, consists of one chain of one 10-methylundecanoyl at the C-1 position and one chain of 12,13-epoxy-octadecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(18:1(9Z)-O(12,13)/i-12:0)

C33H61O9P (632.4053)

PA(18:1(9Z)-O(12,13)/i-12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:1(9Z)-O(12,13)/i-12:0), in particular, consists of one chain of one 12,13-epoxy-octadecenoyl at the C-1 position and one chain of 10-methylundecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

Momordin B

C36H56O9 (632.3924)

Momordin b, also known as oleanolic acid 3-O-glucuronide or 3-O-(b-D-glucopyranuronosyl)oleanolate, is a member of the class of compounds known as triterpene saponins. Triterpene saponins are glycosylated derivatives of triterpene sapogenins. The sapogenin moiety backbone is usually based on the oleanane, ursane, taraxastane, bauerane, lanostane, lupeol, lupane, dammarane, cycloartane, friedelane, hopane, 9b,19-cyclo-lanostane, cycloartane, or cycloartanol skeleton. Momordin b is practically insoluble (in water) and a weakly acidic compound (based on its pKa). Momordin b can be found in bitter gourd, which makes momordin b a potential biomarker for the consumption of this food product. Calenduloside E (CE) is a natural pentacyclic triterpenoid saponin extracted from Aralia elata. Calenduloside E (CE) has anti-apoptotic potent by targeting heat shock protein 90 (Hsp90)[1]. Calenduloside E (CE) is a natural pentacyclic triterpenoid saponin extracted from Aralia elata. Calenduloside E (CE) has anti-apoptotic potent by targeting heat shock protein 90 (Hsp90)[1].

3-O-beta-D-Quinovopyranosyl quinovic acid

C36H56O9 (632.3924)

Rubuside B

C36H56O9 (632.3924)

Rubuside E

C36H56O9 (632.3924)

Rubuside F

C36H56O9 (632.3924)

Myriceric acid A

C39H52O7 (632.3713)

Dichapetalin J

C39H52O7 (632.3713)

Rubuside G

C36H56O9 (632.3924)

(+)-Kopsoffinol

C40H48N4O3 (632.3726)

Laetiposide C

C36H56O9 (632.3924)

Coagulin P

C34H48O11 (632.3196)

Longithorone E

C42H48O5 (632.3502)

3-p-Coumaroylactinidic acid

C39H52O7 (632.3713)

Tetrahydrogambogic acid

C38H48O8 (632.3349)

KBio2_000708

C38H48O8 (632.3349)

Quinovic acid 3-O-rhamnoside

C36H56O9 (632.3924)

bugbanoside A

C35H52O10 (632.356)

Moritoside

C34H48O11 (632.3196)

Cincholic acid 3beta-O-beta-6-deoxy-D-glucopyranoside

C36H56O9 (632.3924)

(5alpha,6alpha,7alpha,22R)-5-hydroxy-1,26-dioxo-6,7:22,26-diepoxyergosta-2,24-dien-27-yl beta-D-glucopyranoside|baimantuoluoside C

C34H48O11 (632.3196)

Myrtucommulone E

C38H48O8 (632.3349)

C36H56O9

C36H56O9 (632.3924)

gomojoside I

C32H56O12 (632.3772)

3beta,23-dihydroxyurs-12,19(29)-dien-28-oic acid 28-beta-D-glucopyranosyl ester

C36H56O9 (632.3924)

MS000070186

C34H48O11 (632.3196)

Methyl-alphitexolid

C39H52O7 (632.3713)

Sonunin I

C36H56O9 (632.3924)

sitoindoside IX|sitoindoside-IX|sitoinoside IX

C34H48O11 (632.3196)

spinosyn alphac

C35H52O10 (632.356)

Euphoppin B

C34H48O11 (632.3196)

Boussingoside C

C35H52O10 (632.356)

quinovic acid-(28->1)-beta-D-fucopyranosyl ester

C36H56O9 (632.3924)

DTXSID90964460

C34H48O11 (632.3196)

gomojoside D

C32H56O12 (632.3772)

Cimifoetiside III

C36H56O9 (632.3924)

C40H48N4O3

C40H48N4O3 (632.3726)

aphanalide D

C34H48O11 (632.3196)

beta-O-acetyl-spirost-5,25(27)-dien-3alpha-yl-O-beta-D-glucopyranoside|tupichinin B

C35H52O10 (632.356)

Vernonioside A1

C35H52O10 (632.356)

aphanalide E

C34H48O11 (632.3196)

Vernonioside B1

C35H52O10 (632.356)

aphanalide C

C34H48O11 (632.3196)

3,4-seco-lupa-4(23),20(30)-diene-3,28-dioic acid 28-O-beta-D-glucopyranoside|acanthosessilioside A

C36H56O9 (632.3924)

walsogyne E

C34H48O11 (632.3196)

3R/S-hydroxytabernamine

C40H48N4O3 (632.3726)

jessic acid alpha-L-arabinopyranoside

C36H56O9 (632.3924)

C35H52O10

C35H52O10 (632.356)

alpinoside

C36H56O9 (632.3924)

NCI60_039302

C34H48O11 (632.3196)

20,27-dihydroxy-3beta-(O-beta-D-glucopyranosyl)-1-oxo-(20S,22R)-witha-5,14,24-trienolide|coagulin P

C34H48O11 (632.3196)

C39H52O7

C39H52O7 (632.3713)

(20S,22R,25S)-furostan-22,25-epoxy-2alpha,3beta,6beta,26-tetraol tetraacetate

C35H52O10 (632.356)

Eriocarpin C

C36H56O9 (632.3924)

MS000176795

C34H48O11 (632.3196)

3beta,23-dihydroxyurs-12,18(19)-dien-28-oic acid 28-beta-D-glucopyranosyl ester

C36H56O9 (632.3924)

dichapetalin C

C39H52O7 (632.3713)

(2R,5S,6S,7R,8R,9R,10S,12S,18R,19S)-18,19-diacetoxy-18,19-epoxy-2,7-dihydroxy-6-[(2Z,4E)-decadienoyloxy]-12-hydroperoxycleroda-3,13(16),14-triene|argutin H

C34H48O11 (632.3196)

(2R,5S,6S,7R,8R,9R,10S,12S,18R,19S)-18,19-diacetoxy-18,19-epoxy-2-[(2Z,4E)-decadienoyloxy]-6,7-dihydroxy-12-hydroperoxycleroda-3,13(16),14-triene|argutin G

C34H48O11 (632.3196)

ent-14-labden-8beta-ol 13alpha-O-beta-D-glucopyranosyl-19-O-alpha-L-rhamnopyranoside

C32H56O12 (632.3772)

3-O-beta-D-glucopyranosyl-11alpha,12alpha-epoxy-olean-28,13-olide

C36H56O9 (632.3924)

oligoporin B

C36H56O9 (632.3924)

3beta-hydroxylup-20(29)-en-28-oic acid 3-O-beta-D-glucuranopyranoside

C36H56O9 (632.3924)

(3beta,5alpha,12beta,14beta,17alpha)-3-(beta-cymaropyranosyloxy)-8,14,17,20-tetrahydroxypregnan-12-yl benzoate

C35H52O10 (632.356)

myriceric acid A|Myriceric acid D

C39H52O7 (632.3713)

Methyl hexa(alpha-hydrocyisovalerate)

C31H52O13 (632.3408)

3beta,23-dihydroxyurs-12,19(20)-dien-28-oic acid 28-beta-D-glucopyranosyl ester

C36H56O9 (632.3924)

pfaffiaglycoside B

C35H52O10 (632.356)

Leu Ala Met Glu Arg

C26H48N8O8S (632.3316)

gypsogenin-28-beta-D-glucoside

C36H56O9 (632.3924)

C36H56O9_Urs-12-ene-27,28-dioic acid, 3-[(6-deoxy-alpha-L-mannopyranosyl)oxy]-, (3beta,5xi,9xi)

C36H56O9 (632.3924)

(2S,3S,4S,5R,6R)-6-[[(3S,6aR,6bS,8aS,14bR)-8a-carboxy-4,4,6a,6b,11,11,14b-heptamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid

C36H56O9 (632.3924)

(1S,2R,4aS,6aR,6bR,10S,12aR,14bS)-1,2,6b,9,9,12a-hexamethyl-10-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydro-1H-picene-4a,6a-dicarboxylic acid

C36H56O9 (632.3924)

Goniomedine B

C40H48N4O3 (632.3726)

(2S,3S,4S,5R,6R)-6-[[(3S,6aR,6bS,8aS,14bR)-8a-carboxy-4,4,6a,6b,11,11,14b-heptamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid_major

C36H56O9 (632.3924)

Tetrahydrogambogic Acid_major

C38H48O8 (632.3349)

Tetrahydrogambogic Acid_minor

C38H48O8 (632.3349)

RESLE

C25H44N8O11 (632.3129)

16,16-dimethyl Prostaglandin E2 p-(p-acetamidobenzamido) phenyl ester

C37H48N2O7 (632.3461)

Coagulin R 3-glucoside

C34H48O11 (632.3196)

Cloversaponin I

C36H56O9 (632.3924)

Lucyoside K

C36H56O9 (632.3924)

cuscutic resinoside A

C32H56O12 (632.3772)

3,9-bis(2,6-di-tert-butyl-4-methylphenoxy)-2,4,8,10-tetraoxa-3,9-diphosphaspiro[ 5.5]undecane (PEP-36)

C35H54O6P2 (632.3395)

Dibutyltin dillaurate

C32H64O4Sn (632.3826)

(7a,17b)-7-[9-[(4,4,5,5,5-Pentafluoropentyl)thio]nonyl]-estra-1,3,5(10)-triene-3,17-diol 17-acetate

C34H49F5O3S (632.3322)

tris(2,5,8,11-tetraoxatridecyl) orthoborate

C27H57BO15 (632.379)

bis[(2-ethyl-1-oxohexyl)oxy]dioctylstannane

C32H64O4Sn (632.3826)

Methyl propionate-PEG12

C28H56O15 (632.3619)

Sitoindoside IX

C34H48O11 (632.3196)

A withanolide saponin that consists of withaferin A attached to a beta-D-glucopyranosyl residue at position 27 via a glycosidic linkage. Isolated from Physalis longifolia, it exhibits antineoplastic activity.

Ajugamarin H1

C34H48O11 (632.3196)

A diterpene lactone isolated from the whole plants of Ajuga ciliata.

ajugamarin G1

C34H48O11 (632.3196)

A diterpene lactone isolated from the whole plant of Ajuga ciliata.

soyasapogenol E 3-O-beta-glucuronide

C36H56O9 (632.3924)

A saponin that is the 3-O-beta-glucuronide of soyasapogenol E.

PA(8:0/PGE2)

C31H53O11P (632.3325)

PA(PGE2/8:0)

C31H53O11P (632.3325)

PA(8:0/PGD2)

C31H53O11P (632.3325)

PA(PGD2/8:0)

C31H53O11P (632.3325)

PA(12:0/18:1(12Z)-O(9S,10R))

C33H61O9P (632.4053)

PA(18:1(12Z)-O(9S,10R)/12:0)

C33H61O9P (632.4053)

PA(i-12:0/18:1(12Z)-O(9S,10R))

C33H61O9P (632.4053)

PA(18:1(12Z)-O(9S,10R)/i-12:0)

C33H61O9P (632.4053)

PA(i-12:0/18:1(9Z)-O(12,13))

C33H61O9P (632.4053)

PA(18:1(9Z)-O(12,13)/i-12:0)

C33H61O9P (632.4053)

[(2R)-2-[(Z)-11-(3-pentyloxiran-2-yl)undec-9-enoyl]oxy-3-phosphonooxypropyl] dodecanoate

C33H61O9P (632.4053)

[(2R)-1-[(Z)-11-(3-pentyloxiran-2-yl)undec-9-enoyl]oxy-3-phosphonooxypropan-2-yl] dodecanoate

C33H61O9P (632.4053)

PA(8:0/20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S))

C31H53O11P (632.3325)

PA(20:4(7E,9E,11Z,13E)-3OH(5S,6R,15S)/8:0)

C31H53O11P (632.3325)

2-[[(2R)-3-acetyloxy-2-[(5R,6R,7Z,9Z,11E,13E,15S,17Z)-5,6,15-trihydroxyicosa-7,9,11,13,17-pentaenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C30H51NO11P+ (632.32)

2-[[(2R)-2-acetyloxy-3-[(5S,6S,7Z,9Z,11E,13E,15R,17Z)-5,6,15-trihydroxyicosa-7,9,11,13,17-pentaenoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C30H51NO11P+ (632.32)

Dinoxin B

C34H48O11 (632.3196)

A natural product found in Datura inoxia.

[4-[(4-acetamidobenzoyl)amino]phenyl] (Z)-7-[(1R,2R,3R)-3-hydroxy-2-[(E,3R)-3-hydroxy-4,4-dimethyloct-1-enyl]-5-oxocyclopentyl]hept-5-enoate

C37H48N2O7 (632.3461)

3-O-trans-p-coumaroyl actinidic acid

C39H52O7 (632.3713)

A pentacyclic triterpenoid that is the cinnamate ester obtained by the formal condensation of the carboxy group of trans-4-coumaric acid with the hydroxy group at position 3 of actinidic acid (the 2alpha,3beta stereoisomer). It is isolated from the roots of Actinidia arguta and exhibits inhibitory activity towards pancreatic lipase.

Argutin H

C34H48O11 (632.3196)

A natural product found in Casearia arguta.

Argutin G

C34H48O11 (632.3196)

A natural product found in Casearia arguta.

gypsogenin 28-beta-D-glucoside

C36H56O9 (632.3924)

N-[(3R,9S,10R)-12-[(2R)-1-hydroxypropan-2-yl]-9-[[(4-methoxyphenyl)methyl-methylamino]methyl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-pyridinecarboxamide

C36H48N4O6 (632.3574)

N-[(3R,9S,10S)-12-[(2S)-1-hydroxypropan-2-yl]-9-[[(4-methoxyphenyl)methyl-methylamino]methyl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-pyridinecarboxamide

C36H48N4O6 (632.3574)

methyl (1S,13R,22S,23R,26E,27R,28S)-13-ethyl-26-ethylidene-21-oxa-9,17,24,29-tetrazadecacyclo[22.11.2.19,13.123,27.01,22.03,20.05,18.06,16.022,29.030,35]nonatriaconta-3,5(18),6(16),19,30,32,34-heptaene-28-carboxylate

C40H48N4O3 (632.3726)

methyl (2R)-2-[(2R,3Z,12bS)-3-ethylidene-2,4,6,7,12,12b-hexahydro-1H-indolo[2,3-a]quinolizin-2-yl]-2-[(1R,9S,12S,13S,14S,19S,21S)-14-ethyl-10-oxa-8,16-diazahexacyclo[11.5.2.11,8.02,7.016,19.012,21]henicosa-2,4,6-trien-9-yl]acetate

C40H48N4O3 (632.3726)

methyl (1S,13R,22S,23S,26E,27S)-13-ethyl-26-ethylidene-21-oxa-9,17,24,29-tetrazadecacyclo[22.11.2.19,13.123,27.01,22.03,20.05,18.06,16.022,29.030,35]nonatriaconta-3,5(18),6(16),19,30,32,34-heptaene-28-carboxylate

C40H48N4O3 (632.3726)

PE-Cer 15:3;2O/18:5

C35H57N2O6P (632.3954)

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoxy]propan-2-yl] undecanoate

C33H61O9P (632.4053)

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-undecoxypropan-2-yl] (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate

C33H61O9P (632.4053)

[1-[(2-butanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (10Z,13Z,16Z)-docosa-10,13,16-trienoate

C32H57O10P (632.3689)

[1-hydroxy-3-[hydroxy-(3-hydroxy-2-octanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (9Z,12Z,15Z)-octadeca-9,12,15-trienoate

C32H57O10P (632.3689)

[1-[(2-hexanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (11Z,14Z,17Z)-icosa-11,14,17-trienoate

C32H57O10P (632.3689)

[1-[(2-decanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate

C32H57O10P (632.3689)

[1-butanoyloxy-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxypropan-2-yl] (10Z,13Z,16Z)-docosa-10,13,16-trienoate

C32H57O10P (632.3689)

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexanoyloxypropan-2-yl] (11Z,14Z,17Z)-icosa-11,14,17-trienoate

C32H57O10P (632.3689)

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-octanoyloxypropan-2-yl] (9Z,12Z,15Z)-octadeca-9,12,15-trienoate

C32H57O10P (632.3689)

[2-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxy-3-phosphonooxypropyl] (4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoate

C35H53O8P (632.3478)

[1-decanoyloxy-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxypropan-2-yl] (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate

C32H57O10P (632.3689)

[1-[(4E,7E)-deca-4,7-dienoyl]oxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoate

C35H52O10 (632.356)

[1-[(E)-dec-4-enoyl]oxy-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxypropan-2-yl] (4E,7E)-hexadeca-4,7-dienoate

C32H57O10P (632.3689)

[1-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-phosphonooxypropan-2-yl] (9E,11E,13E)-hexadeca-9,11,13-trienoate

C35H53O8P (632.3478)

[2-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxy-3-phosphonooxypropyl] (7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoate

C35H53O8P (632.3478)

[2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-phosphonooxypropyl] (9E,11E,13E)-hexadeca-9,11,13-trienoate

C35H53O8P (632.3478)

[1-decanoyloxy-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxypropan-2-yl] (9E,11E,13E)-hexadeca-9,11,13-trienoate

C32H57O10P (632.3689)

Momordin B

C36H56O9 (632.3924)

Oleanolic acid 3-O-beta-D-glucosiduronic acid is a beta-D-glucosiduronic acid. It is functionally related to an oleanolic acid. Calenduloside E is a natural product found in Anredera baselloides, Polyscias scutellaria, and other organisms with data available. See also: Calendula Officinalis Flower (part of). Calenduloside E (CE) is a natural pentacyclic triterpenoid saponin extracted from Aralia elata. Calenduloside E (CE) has anti-apoptotic potent by targeting heat shock protein 90 (Hsp90)[1]. Calenduloside E (CE) is a natural pentacyclic triterpenoid saponin extracted from Aralia elata. Calenduloside E (CE) has anti-apoptotic potent by targeting heat shock protein 90 (Hsp90)[1].

MGDG O-27:7

C36H56O9 (632.3924)

MGMG 27:7

C36H56O9 (632.3924)

SQMG 22:4

C31H52O11S (632.323)

DGGA 23:1;O

C32H56O12 (632.3772)

DGGA 25:7

C34H48O11 (632.3196)

MGGA 26:7

C35H52O10 (632.356)

PA O-18:0/12:3;O2

C33H61O9P (632.4053)

PA O-29:4;O3

C32H57O10P (632.3689)

PA O-30:3;O2

C33H61O9P (632.4053)

PA P-18:0/11:3;O3

C32H57O10P (632.3689)

PA P-18:0/12:2;O2

C33H61O9P (632.4053)

PA 16:0/13:3;O2

C32H57O10P (632.3689)

PA 16:1/12:3;O3

C31H53O11P (632.3325)

PA 20:1/8:3;O3

C31H53O11P (632.3325)

PA 20:2/8:2;O3

C31H53O11P (632.3325)

PA 20:2/9:1;O2

C32H57O10P (632.3689)

PA 22:0/7:3;O2

C32H57O10P (632.3689)

PA 22:1/7:2;O2

C32H57O10P (632.3689)

PA 22:1/8:1;O

C33H61O9P (632.4053)

PA 28:4;O3

C31H53O11P (632.3325)

PA 29:3;O2

C32H57O10P (632.3689)

PA 30:2;O

C33H61O9P (632.4053)

PA 32:8

C35H53O8P (632.3478)

LPGP O-22:1

C28H58O11P2 (632.3454)

LPGP P-22:0

C28H58O11P2 (632.3454)

PG O-25:5;O2

C31H53O11P (632.3325)

PG O-26:4;O

C32H57O10P (632.3689)

PG P-16:0/9:4;O2

C31H53O11P (632.3325)

PG P-18:0/8:3;O

C32H57O10P (632.3689)

PG P-18:1/7:3;O2

C31H53O11P (632.3325)

PG P-18:1/8:2;O

C32H57O10P (632.3689)

PG P-20:1/6:2;O

C32H57O10P (632.3689)

PG 18:1/7:3;O

C31H53O11P (632.3325)

PG 20:3/5:1;O

C31H53O11P (632.3325)

PG 25:4;O

C31H53O11P (632.3325)

PG 22:2/4:1

C32H57O10P (632.3689)

PG 26:3

C32H57O10P (632.3689)

PG 4:0_22:3

C32H57O10P (632.3689)

PEth 28:2;O

C33H61O9P (632.4053)

PEth 30:8

C35H53O8P (632.3478)

PM 29:2;O

C33H61O9P (632.4053)

PM 31:8

C35H53O8P (632.3478)

CerPE 15:3;O2/18:5

C35H57N2O6P (632.3954)

ST 25:0;O7;GlcA

C31H52O13 (632.3408)

ST 28:5;O5;GlcA

C34H48O11 (632.3196)

ST 29:4;O4;GlcA

C35H52O10 (632.356)

ST 25:1;O8;Hex

C31H52O13 (632.3408)

ST 26:0;O7;Hex

C32H56O12 (632.3772)

ST 28:6;O6;Hex

C34H48O11 (632.3196)

ST 29:5;O5;Hex

C35H52O10 (632.356)

(1s,3r,5r,6as,7s,8s,9r,10r,10as)-1,3-bis(acetyloxy)-7-[(2r)-2-hydroperoxy-3-methylidenepent-4-en-1-yl]-5,9-dihydroxy-7,8-dimethyl-1h,3h,5h,6h,6ah,8h,9h,10h-naphtho[1,8a-c]furan-10-yl (2z,4e)-deca-2,4-dienoate

C34H48O11 (632.3196)

8-(acetyloxy)-8a-[(acetyloxy)methyl]-5,6-dimethyl-5-{2-[(2-methylbutanoyl)oxy]-2-(5-oxo-2h-furan-3-yl)ethyl}-hexahydro-2h-spiro[naphthalene-1,2'-oxiran]-4-yl 2-methylbut-2-enoate

C34H48O11 (632.3196)

(6r,14r)-13-hydroxy-6,14-diisopropyl-2,2,4,4,8,8,10,10-octamethyl-12-(2-methylpropanoyl)-6,14-dihydro-5,11-dioxapentaphene-1,3,7,9-tetrone

C38H48O8 (632.3349)

(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl (2r,4as,6as,6br,8ar,10r,11r,12ar,12br)-10,11-dihydroxy-1,2,6a,6b,9,9,12a-heptamethyl-3,4,5,6,7,8,8a,10,11,12,12b,13-dodecahydro-2h-picene-4a-carboxylate

C36H56O9 (632.3924)

methyl (1r,9r,16r,18r,21s)-6-[(15r,17r,19s)-15-[(1r)-1-hydroxyethyl]-1,11-diazapentacyclo[9.6.2.0²,⁷.0⁸,¹⁸.0¹⁵,¹⁹]nonadeca-2,4,6,8(18)-tetraen-17-yl]-2,12-diazahexacyclo[14.2.2.1⁹,¹².0¹,⁹.0³,⁸.0¹⁶,²¹]henicosa-3,5,7-triene-18-carboxylate

C40H48N4O3 (632.3726)

(1s,2r,4as,6ar,6br,8ar,10s,12ar,12br,14br)-10-hydroxy-1,2,6b,9,9,12a-hexamethyl-4a-({[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}carbonyl)-2,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydro-1h-picene-6a-carboxylic acid

C36H56O9 (632.3924)

methyl (1s,12r,14s,18s)-12-[(1r,15s,17s,18s)-17-ethyl-7-methoxy-3,13-diazapentacyclo[13.3.1.0²,¹⁰.0⁴,⁹.0¹³,¹⁸]nonadeca-2(10),4,6,8-tetraen-6-yl]-15-ethylidene-10,17-diazatetracyclo[12.3.1.0³,¹¹.0⁴,⁹]octadeca-3(11),4,6,8-tetraene-18-carboxylate

C40H48N4O3 (632.3726)

15',16',19'-tris(acetyloxy)-5,7',9',13'-tetramethyl-5'-oxaspiro[oxolane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-5-ylmethyl acetate

C35H52O10 (632.356)

(2z,6r)-6-[(1r,3as,5ar,7r,9as,11s,11ar)-7-hydroxy-3a,6,6,9a,11a-pentamethyl-11-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,5h,5ah,7h,8h,9h,11h-cyclopenta[a]phenanthren-1-yl]-2-methylhept-2-enoic acid

C36H56O9 (632.3924)

(3s,6s,9s,12s)-3-benzyl-9-{[4-(buta-2,3-dien-1-yloxy)-3-hydroxyphenyl]methyl}-5,11-dihydroxy-1,7-dimethyl-6,12-bis(2-methylpropyl)-1,4,7,10-tetraazacyclododeca-4,10-diene-2,8-dione

C36H48N4O6 (632.3574)

2,3-dihydroxy-12,19(29)-ursadien-28-oic acid; (2α,3α)-form,beta-d-glucopyranosyl ester

C36H56O9 (632.3924)

{"Ingredient_id": "HBIN004032","Ingredient_name": "2,3-dihydroxy-12,19(29)-ursadien-28-oic acid; (2\u03b1,3\u03b1)-form,beta-d-glucopyranosyl ester","Alias": "NA","Ingredient_formula": "C36H56O9","Ingredient_Smile": "NA","Ingredient_weight": "632.82","OB_score": "NA","CAS_id": "146787-96-4","SymMap_id": "NA","TCMID_id": "NA","TCMSP_id": "NA","TCM_ID_id": "8946","PubChem_id": "NA","DrugBank_id": "NA"}

6″-O-trans-sinapoylgenipin gentiobioside

C34H48O11 (632.3196)

{"Ingredient_id": "HBIN012724","Ingredient_name": "6\u2033-O-trans-sinapoylgenipin gentiobioside","Alias": "NA","Ingredient_formula": "C34H48O11","Ingredient_Smile": "CC1C(C(C(OC1COC2C(C(C(C(O2)CO)O)O)O)OC(=O)C(=CC=CC(=CC=CC=C(C)C=CC=C(C)C=O)C)C)O)C","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "40184","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl (2r,4as,6as,6br,8ar,10s,11r,12ar,12br)-10,11-dihydroxy-1,2,6a,6b,9,9,12a-heptamethyl-3,4,5,6,7,8,8a,10,11,12,12b,13-dodecahydro-2h-picene-4a-carboxylate

C36H56O9 (632.3924)

3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl 10,11-dihydroxy-1,2,6a,6b,9,9,12a-heptamethyl-3,4,5,6,7,8,8a,10,11,12,12b,13-dodecahydro-2h-picene-4a-carboxylate

C36H56O9 (632.3924)

(2r)-2-[(1r,3ar,4r,9as,11ar)-3a,6,6,9a,11a-pentamethyl-7-oxo-4-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,4h,5h,5ah,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-6-methylhept-5-enoic acid

C36H56O9 (632.3924)

(2s,3s,4s,5r,6s)-6-{[(3s,4ar,6ar,6bs,8as,12as,14ar,14br)-8a-carboxy-4,4,6a,6b,11,11,14b-heptamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy}-3,4,5-trihydroxyoxane-2-carboxylic acid

C36H56O9 (632.3924)

(2r,3r,4r,5r,6s)-2-{[(1r,4ar,5s,6r,8as)-6-hydroxy-1,4a,6-trimethyl-5-[(3s)-3-methyl-3-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}pent-4-en-1-yl]-hexahydro-2h-naphthalen-1-yl]methoxy}-6-methyloxane-3,4,5-triol

C32H56O12 (632.3772)

(6r)-6-[(1r)-1-[(1s,3br,7s,9ar,9bs,11ar)-9a,11a-dimethyl-9-oxo-7-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3bh,4h,5h,7h,8h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]-1-hydroxyethyl]-3-(hydroxymethyl)-4-methyl-5,6-dihydropyran-2-one

C34H48O11 (632.3196)

3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl 10,11-dihydroxy-1,2,6a,6b,9,9,12a-heptamethyl-4,5,6,7,8,8a,10,11,12,12b,13,14b-dodecahydro-3h-picene-4a-carboxylate

C36H56O9 (632.3924)

(1s,3r,5r,6as,7s,8s,9r,10s,10as)-1,3-bis(acetyloxy)-7-[(2r)-2-hydroperoxy-3-methylidenepent-4-en-1-yl]-5,9-dihydroxy-7,8-dimethyl-1h,3h,5h,6h,6ah,8h,9h,10h-naphtho[1,8a-c]furan-10-yl (2e,4e)-deca-2,4-dienoate

C34H48O11 (632.3196)

3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl 10-hydroxy-9-(hydroxymethyl)-2,6a,6b,9,12a-pentamethyl-1-methylidene-2,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylate

C36H56O9 (632.3924)

methyl (1r,9r,16s,18r,21s)-6-[(15r,17r,19s)-15-(1-hydroxyethyl)-1,11-diazapentacyclo[9.6.2.0²,⁷.0⁸,¹⁸.0¹⁵,¹⁹]nonadeca-2,4,6,8(18)-tetraen-17-yl]-2,12-diazahexacyclo[14.2.2.1⁹,¹².0¹,⁹.0³,⁸.0¹⁶,²¹]henicosa-3,5,7-triene-18-carboxylate

C40H48N4O3 (632.3726)

[3,4-bis(acetyloxy)-5-hydroxy-6-[4-hydroxy-5-methyl-2-(3,7,11-trimethyl-9-oxododeca-2,6-dien-1-yl)phenoxy]oxan-2-yl]methyl acetate

C34H48O11 (632.3196)

3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl 10-hydroxy-9-(hydroxymethyl)-1,2,6a,6b,9,12a-hexamethyl-4,5,6,7,8,8a,10,11,12,12b,13,14b-dodecahydro-3h-picene-4a-carboxylate

C36H56O9 (632.3924)

(4r,4ar,5s,6r,8s,8ar)-8-(acetyloxy)-8a-[(acetyloxy)methyl]-5,6-dimethyl-5-[(2s)-2-{[(2s)-2-methylbutanoyl]oxy}-2-(5-oxo-2h-furan-3-yl)ethyl]-hexahydro-2h-spiro[naphthalene-1,2'-oxiran]-4-yl (2e)-2-methylbut-2-enoate

C34H48O11 (632.3196)

[3,4-bis(acetyloxy)-5-hydroxy-6-[4-hydroxy-2-(9-hydroxy-3,7,11-trimethyldodeca-2,6,10-trien-1-yl)-5-methylphenoxy]oxan-2-yl]methyl acetate

C34H48O11 (632.3196)

(1s,3r,5r,6as,7s,8s,9r,10r,10as)-1,3-bis(acetyloxy)-7-[(2r)-2-hydroperoxy-3-methylidenepent-4-en-1-yl]-9,10-dihydroxy-7,8-dimethyl-1h,3h,5h,6h,6ah,8h,9h,10h-naphtho[1,8a-c]furan-5-yl (2z,4e)-deca-2,4-dienoate

C34H48O11 (632.3196)

3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl 10,11-dihydroxy-1,2,6a,6b,9,9,12a-heptamethyl-2,3,4,5,6,7,8,8a,10,11,12,12b-dodecahydro-1h-picene-4a-carboxylate

C36H56O9 (632.3924)

(1r,2r,3r,4s,5s,7r,8r,9r,10r,11s,13s,15r)-2,4-bis(acetyloxy)-8,16-dihydroxy-5,9,12,12-tetramethyl-7-{[(2e)-2-methylbut-2-enoyl]oxy}-17-oxapentacyclo[7.6.2.0¹,¹⁰.0³,⁷.0¹¹,¹³]heptadecan-15-yl (2e)-2-methylbut-2-enoate

C34H48O11 (632.3196)

[(2r,3s,4r,5r,6s)-3,4-bis(acetyloxy)-5-hydroxy-6-{4-hydroxy-2-[(2e,6e,9r)-9-hydroxy-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]-5-methylphenoxy}oxan-2-yl]methyl acetate

C34H48O11 (632.3196)

(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl (2r,4as,6as,6br,8ar,9r,10s,12ar,12br,14bs)-10-hydroxy-9-(hydroxymethyl)-2,6a,6b,9,12a-pentamethyl-1-methylidene-2,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylate

C36H56O9 (632.3924)

(2s,3s,4r,5s,6r)-5-(acetyloxy)-6-{[(1r,3s,5s,7s,10s,11r,14r,15r,18r)-18-hydroxy-10,14-dimethyl-15-(5-oxo-2h-furan-3-yl)-2-oxapentacyclo[9.7.0.0¹,³.0⁵,¹⁰.0¹⁴,¹⁸]octadecan-7-yl]oxy}-4-methoxy-2-methyloxan-3-yl acetate

C34H48O11 (632.3196)

6-(7-hydroxy-3a,6,6,9a,11a-pentamethyl-11-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,5h,5ah,7h,8h,9h,11h-cyclopenta[a]phenanthren-1-yl)-2-methylhept-2-enoic acid

C36H56O9 (632.3924)

(1s,2s,4s,5r,6s,9s,11r,14r,15s,18s,23r)-6,10,10,14,15,21,21-heptamethyl-9-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-3,24-dioxaheptacyclo[16.5.2.0¹,¹⁵.0²,⁴.0⁵,¹⁴.0⁶,¹¹.0¹⁸,²³]pentacosan-25-one

C36H56O9 (632.3924)

methyl 2-{14-ethyl-10-oxa-8,16-diazahexacyclo[11.5.2.1¹,⁸.0²,⁷.0¹⁶,¹⁹.0¹²,²¹]henicosa-2,4,6-trien-9-yl}-2-{3-ethylidene-1h,2h,4h,6h,7h,12h,12bh-indolo[2,3-a]quinolizin-2-yl}acetate

C40H48N4O3 (632.3726)

(1s)-2-[(4r,4ar,5s,6r,8s,8ar)-8-(acetyloxy)-8a-[(acetyloxy)methyl]-5,6-dimethyl-4-{[(2s)-2-methylbutanoyl]oxy}-hexahydro-2h-spiro[naphthalene-1,2'-oxiran]-5-yl]-1-(5-oxo-2h-furan-3-yl)ethyl (2e)-2-methylbut-2-enoate

C34H48O11 (632.3196)

6-[1-(9a,11a-dimethyl-9-oxo-7-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3bh,4h,6h,7h,8h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl)-1-hydroxyethyl]-3-(hydroxymethyl)-4-methyl-5,6-dihydropyran-2-one

C34H48O11 (632.3196)

6-hydroxy-2,16-dimethyl-15-{1-[4-methyl-6-oxo-5-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)-2,3-dihydropyran-2-yl]ethyl}-8-oxapentacyclo[9.7.0.0²,⁷.0⁷,⁹.0¹²,¹⁶]octadec-4-en-3-one

C34H48O11 (632.3196)

(1s,2r,4as,6ar,6br,8ar,10s,12ar,12br,14bs)-1,2,6b,9,9,12a-hexamethyl-10-{[(2r,3s,4s,5s,6r)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}-2,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydro-1h-picene-4a,6a-dicarboxylic acid

C36H56O9 (632.3924)

3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl 10,11-dihydroxy-2,6a,6b,9,9,12a-hexamethyl-1-methylidene-2,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylate

C36H56O9 (632.3924)

(2s,3s,4s,5r,6r)-6-{[(3s,4ar,6ar,6bs,8ar,12ar,14ar,14br)-8a-carboxy-4,4,6a,6b,11,11,14b-heptamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy}-3,4,5-trihydroxyoxane-2-carboxylic acid

C36H56O9 (632.3924)

(2r)-2-[(1r,3ar,4s,5ar,9as,11ar)-3a,6,6,9a,11a-pentamethyl-7-oxo-4-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,4h,5h,5ah,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-6-methylhept-5-enoic acid

C36H56O9 (632.3924)

[3,4-bis(acetyloxy)-5-hydroxy-6-{4-hydroxy-2-[(2e,6e,9s)-9-hydroxy-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]-5-methylphenoxy}oxan-2-yl]methyl acetate

C34H48O11 (632.3196)

2,2,6b,9,9,12a-hexamethyl-10-[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy]-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a,6a-dicarboxylic acid

C36H56O9 (632.3924)

(6r)-6-[(1r)-1-[(1s,3br,7r,9ar,9bs,11ar)-9a,11a-dimethyl-9-oxo-7-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3bh,4h,6h,7h,8h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]-1-hydroxyethyl]-3-(hydroxymethyl)-4-methyl-5,6-dihydropyran-2-one

C34H48O11 (632.3196)

(2s,3s,4s,5r,6s)-6-{[(3s,4ar,6as,6br,8ar,12ar,14ar,14br)-8a-carboxy-4,4,6a,6b,11,11,14b-heptamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy}-3,4,5-trihydroxyoxane-2-carboxylic acid

C36H56O9 (632.3924)

(4as,6ar,6br,8as,10s,12ar,12br,14bs)-2,2,6b,9,9,12a-hexamethyl-10-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a,6a-dicarboxylic acid

C36H56O9 (632.3924)

4-({5-[(2-{[5-({3-[(5-aminopentyl)(hydroxy)carbamoyl]-1-hydroxypropylidene}amino)pentyl]-c-hydroxycarbonimidoyl}ethyl)(hydroxy)carbamoyl]pentyl}(hydroxy)carbamoyl)butanoic acid

C28H52N6O10 (632.3745)

[3,4-bis(acetyloxy)-5-hydroxy-6-{4-hydroxy-5-methyl-2-[(2e,6e)-3,7,11-trimethyl-9-oxododeca-2,6-dien-1-yl]phenoxy}oxan-2-yl]methyl acetate

C34H48O11 (632.3196)

(1s,2r,4as,6ar,6br,8ar,10s,12ar,12br,14bs)-1,2,6b,9,9,12a-hexamethyl-10-{[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}-2,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydro-1h-picene-4a,6a-dicarboxylic acid

C36H56O9 (632.3924)

3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl 10-hydroxy-9-(hydroxymethyl)-1,2,6a,6b,9,12a-hexamethyl-3,4,5,6,7,8,8a,10,11,12,12b,13-dodecahydro-2h-picene-4a-carboxylate

C36H56O9 (632.3924)

3-(9a,11a-dimethyl-7-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,3ah,5h,5ah,6h,7h,8h,9h,11h-cyclopenta[a]phenanthren-1-yl)-4-hydroxy-5-(2-isopropyl-3-methyloxiran-2-yl)oxolan-2-one

C35H52O10 (632.356)

(1s,2s,4s,5r,10r,11s,14r,15r,18s)-5-hydroxy-10,14-dimethyl-15-[(1s)-1-[(2r)-4-methyl-6-oxo-5-({[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)-2,3-dihydropyran-2-yl]ethyl]-3-oxapentacyclo[9.7.0.0²,⁴.0⁵,¹⁰.0¹⁴,¹⁸]octadec-7-en-9-one

C34H48O11 (632.3196)

(1s)-2-[(1r,4r,4ar,5s,6r,8s,8ar)-8-(acetyloxy)-8a-[(acetyloxy)methyl]-5,6-dimethyl-4-{[(2r)-2-methylbutanoyl]oxy}-hexahydro-2h-spiro[naphthalene-1,2'-oxiran]-5-yl]-1-(5-oxo-2h-furan-3-yl)ethyl (2e)-2-methylbut-2-enoate

C34H48O11 (632.3196)

(2s,3r,4r,5r)-2-[(1s,1's,2r,4s,4'r,5r,5'r,6'r,10's,12's,13's,15's,16'r,18's,21'r)-4',5,6',12',17',17'-hexamethyl-3,9'-dioxaspiro[bicyclo[3.1.0]hexane-2,8'-hexacyclo[11.9.0.0¹,²¹.0⁴,¹².0⁵,¹⁰.0¹⁶,²¹]docosane]-4,15'-dioloxy]oxane-3,4,5-triol

C36H56O9 (632.3924)

quinovin

C36H56O9 (632.3924)

(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl (1s,2r,4as,6as,6br,8ar,10s,11r,12as,12br)-10,11-dihydroxy-1,2,6a,6b,9,9,12a-heptamethyl-2,3,4,5,6,7,8,8a,10,11,12,12b-dodecahydro-1h-picene-4a-carboxylate

C36H56O9 (632.3924)

6-{[(1r,3as,5ar,5br,7ar,9s,11ar,11br,13ar,13br)-3a-carboxy-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-hexadecahydrocyclopenta[a]chrysen-9-yl]oxy}-3,4,5-trihydroxyoxane-2-carboxylic acid

C36H56O9 (632.3924)

(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl (2r,4as,6as,6br,8ar,9r,10s,12ar,12br)-10-hydroxy-9-(hydroxymethyl)-1,2,6a,6b,9,12a-hexamethyl-3,4,5,6,7,8,8a,10,11,12,12b,13-dodecahydro-2h-picene-4a-carboxylate

C36H56O9 (632.3924)

(1s,3r,5r,6as,7s,8s,9r,10s,10as)-1,3-bis(acetyloxy)-7-[(2r)-2-hydroperoxy-3-methylidenepent-4-en-1-yl]-9,10-dihydroxy-7,8-dimethyl-1h,3h,5h,6h,6ah,8h,9h,10h-naphtho[1,8a-c]furan-5-yl (2z,4e)-deca-2,4-dienoate

C34H48O11 (632.3196)

1,3-bis(acetyloxy)-7-(2-hydroperoxy-3-methylidenepent-4-en-1-yl)-5,9-dihydroxy-7,8-dimethyl-1h,3h,5h,6h,6ah,8h,9h,10h-naphtho[1,8a-c]furan-10-yl deca-2,4-dienoate

C34H48O11 (632.3196)

5-hydroxy-10,14-dimethyl-15-{1-[4-methyl-6-oxo-5-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)-2,3-dihydropyran-2-yl]ethyl}-3-oxapentacyclo[9.7.0.0²,⁴.0⁵,¹⁰.0¹⁴,¹⁸]octadec-7-en-9-one

C34H48O11 (632.3196)

(2z,6r)-6-[(1r,3as,5ar,7r,9as,11r,11ar)-7-hydroxy-3a,6,6,9a,11a-pentamethyl-11-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,5h,5ah,7h,8h,9h,11h-cyclopenta[a]phenanthren-1-yl]-2-methylhept-2-enoic acid

C36H56O9 (632.3924)

5-(acetyloxy)-6-{[18-hydroxy-10,14-dimethyl-15-(5-oxo-2h-furan-3-yl)-2-oxapentacyclo[9.7.0.0¹,³.0⁵,¹⁰.0¹⁴,¹⁸]octadecan-7-yl]oxy}-4-methoxy-2-methyloxan-3-yl acetate

C34H48O11 (632.3196)

(3e,10e,26z)-4,11,27-trimethyl-17,31,33,35-tetraoxo-14-(prop-1-en-2-yl)pentacyclo[27.2.2.1⁶,²³.1¹⁵,¹⁹.0⁷,²¹]pentatriaconta-1(32),3,10,15,18,23(34),26,29-octaene-7-carbaldehyde

C42H48O5 (632.3502)

(3r,5s)-3-[(1r,2r,3ar,5as,7s,9as,11as)-2-hydroxy-9a,11a-dimethyl-7-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,3ah,5h,5ah,6h,7h,8h,9h,11h-cyclopenta[a]phenanthren-1-yl]-5-[(2r,3s)-2-isopropyl-3-methyloxiran-2-yl]oxolan-2-one

C35H52O10 (632.356)

(4as,6ar,6br,8ar,10s,12ar,12br,14bs)-2,2,6b,9,9,12a-hexamethyl-10-{[(2s,3s,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a,6a-dicarboxylic acid

C36H56O9 (632.3924)

methyl 10-(4-methoxybenzoyloxy)-4,5,9,9,12-pentamethyl-20-oxo-18-(prop-1-en-2-yl)-19-oxahexacyclo[16.2.2.0¹,¹⁷.0⁴,¹⁶.0⁵,¹³.0⁸,¹²]docosane-11-carboxylate

C39H52O7 (632.3713)

(2s,3s,4s,5r,6r)-6-{[(3s,4r,4ar,6ar,6bs,8as,12as,14ar,14br)-8a-carboxy-4-(hydroxymethyl)-4,6a,6b,14b-tetramethyl-11-methylidene-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy}-3,4,5-trihydroxyoxane-2-carboxylic acid

C35H52O10 (632.356)

(2s,3r,4s,5r)-2-[(1r,1's,2r,4'r,5s,5'r,6'r,10's,12'r,16's,18's,20's,21's)-4',5,6',12',17',17'-hexamethyl-3,6,9'-trioxaspiro[bicyclo[3.1.0]hexane-2,8'-hexacyclo[11.9.0.0¹,²¹.0⁴,¹².0⁵,¹⁰.0¹⁶,²¹]docosan]-13'-ene-4,20'-dioloxy]oxane-3,4,5-triol

C35H52O10 (632.356)

(1s,2r,4as,6ar,6br,8ar,10s,12ar,12br,14bs)-1,2,6b,9,9,12a-hexamethyl-10-{[(2r,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}-2,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydro-1h-picene-4a,6a-dicarboxylic acid

C36H56O9 (632.3924)

(4as,6ar,6br,8ar,12ar,12br,14bs)-6a-({[(2e)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy}methyl)-2,2,6b,9,9,12a-hexamethyl-10-oxo-3,4,5,6,7,8,8a,11,12,12b,13,14b-dodecahydro-1h-picene-4a-carboxylic acid

C39H52O7 (632.3713)

3-[(3r,3ar,3br,5ar,6s,7s,9ar,9br,11as)-6,9a,9b-trimethyl-3,7-bis(prop-1-en-2-yl)-11a-({[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}carbonyl)-dodecahydro-1h-cyclopenta[a]phenanthren-6-yl]propanoic acid

C36H56O9 (632.3924)

(3e,6s,7s,10e,14s,21r,26z)-4,11,27-trimethyl-17,31,33,35-tetraoxo-14-(prop-1-en-2-yl)pentacyclo[27.2.2.1⁶,²³.1¹⁵,¹⁹.0⁷,²¹]pentatriaconta-1(32),3,10,15,18,23(34),26,29-octaene-7-carbaldehyde

C42H48O5 (632.3502)

n-[(2s)-1-oxo-1-{[(8z,10z,16z)-3,15,22,24-tetrahydroxy-5-methoxy-14,16-dimethyl-2-azabicyclo[18.3.1]tetracosa-1(24),2,6,8,10,16,20,22-octaen-13-yl]oxy}propan-2-yl]benzenecarboximidic acid

C36H44N2O8 (632.3098)

methyl (1r,4r,5r,8s,10s,11s,12r,13r,16r,17r,18s)-10-(4-methoxybenzoyloxy)-4,5,9,9,12-pentamethyl-20-oxo-18-(prop-1-en-2-yl)-19-oxahexacyclo[16.2.2.0¹,¹⁷.0⁴,¹⁶.0⁵,¹³.0⁸,¹²]docosane-11-carboxylate

C39H52O7 (632.3713)

3-(2-hydroxy-9a,11a-dimethyl-7-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,3ah,5h,5ah,6h,7h,8h,9h,11h-cyclopenta[a]phenanthren-1-yl)-5-(2-isopropyl-3-methyloxiran-2-yl)oxolan-2-one

C35H52O10 (632.356)

1,3-bis(acetyloxy)-7-(2-hydroperoxy-3-methylidenepent-4-en-1-yl)-9,10-dihydroxy-7,8-dimethyl-1h,3h,5h,6h,6ah,8h,9h,10h-naphtho[1,8a-c]furan-5-yl deca-2,4-dienoate

C34H48O11 (632.3196)

(4as,6ar,6br,12ar,12br,14bs)-1,2,6b,9,9,12a-hexamethyl-10-[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy]-2,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydro-1h-picene-4a,6a-dicarboxylic acid

C36H56O9 (632.3924)

(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl (2r,4as,6as,6br,8ar,10s,11r,12ar,12br,14bs)-10,11-dihydroxy-2,6a,6b,9,9,12a-hexamethyl-1-methylidene-2,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylate

C36H56O9 (632.3924)

2-[8-(acetyloxy)-8a-[(acetyloxy)methyl]-5,6-dimethyl-4-[(2-methylbutanoyl)oxy]-hexahydro-2h-spiro[naphthalene-1,2'-oxiran]-5-yl]-1-(5-oxo-2h-furan-3-yl)ethyl 2-methylbut-2-enoate

C34H48O11 (632.3196)

[(2r,3s,4r,5r,6s)-3,4-bis(acetyloxy)-5-hydroxy-6-{4-hydroxy-5-methyl-2-[(2e,6e)-3,7,11-trimethyl-9-oxododeca-2,6-dien-1-yl]phenoxy}oxan-2-yl]methyl acetate

C34H48O11 (632.3196)

methyl 6,7-dihydroxy-2-[(1s,2r,3r,5r,6r,9s,14s,15r,18s)-3-hydroxy-2,6,14-trimethyl-9-phenyl-8-oxahexacyclo[16.3.1.0¹,¹⁸.0²,¹⁵.0⁵,¹⁴.0⁶,¹¹]docosa-11,16-dien-19-yl]-6-methyl-4-oxoheptanoate

C39H52O7 (632.3713)

(2s,3s,4s,5r,6r)-6-{[(1r,3as,5ar,5br,7ar,9s,11ar,11br,13ar,13br)-3a-carboxy-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-hexadecahydrocyclopenta[a]chrysen-9-yl]oxy}-3,4,5-trihydroxyoxane-2-carboxylic acid

C36H56O9 (632.3924)

(3s,5r)-3-[(1r,2r,3r,5r,6r,9s,14s,15r,17r,18s,19s)-3,17-dihydroxy-9-(4-methoxyphenyl)-2,6,14-trimethyl-8-oxahexacyclo[16.3.1.0¹,¹⁸.0²,¹⁵.0⁵,¹⁴.0⁶,¹¹]docos-11-en-19-yl]-5-[(1e)-3-hydroxy-2-methylprop-1-en-1-yl]oxolan-2-one

C39H52O7 (632.3713)

methyl 6-[15-(1-hydroxyethyl)-1,11-diazapentacyclo[9.6.2.0²,⁷.0⁸,¹⁸.0¹⁵,¹⁹]nonadeca-2,4,6,8(18)-tetraen-17-yl]-2,12-diazahexacyclo[14.2.2.1⁹,¹².0¹,⁹.0³,⁸.0¹⁶,²¹]henicosa-3,5,7-triene-18-carboxylate

C40H48N4O3 (632.3726)

(4as,6as,6br,8ar,9s,10s,12ar,12br,14bs)-9-formyl-2,2,6a,6b,9,12a-hexamethyl-10-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylic acid

C36H56O9 (632.3924)

(3s,4r,5s)-3-[(1r,3ar,5as,7s,9as,11ar)-9a,11a-dimethyl-7-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,3ah,5h,5ah,6h,7h,8h,9h,11h-cyclopenta[a]phenanthren-1-yl]-4-hydroxy-5-[(2r,3s)-2-isopropyl-3-methyloxiran-2-yl]oxolan-2-one

C35H52O10 (632.356)

methyl (1r,9r,16r,18r,21s)-6-[(15s,17s,19r)-15-[(1r)-1-hydroxyethyl]-1,11-diazapentacyclo[9.6.2.0²,⁷.0⁸,¹⁸.0¹⁵,¹⁹]nonadeca-2,4,6,8(18)-tetraen-17-yl]-2,12-diazahexacyclo[14.2.2.1⁹,¹².0¹,⁹.0³,⁸.0¹⁶,²¹]henicosa-3,5,7-triene-18-carboxylate

C40H48N4O3 (632.3726)

(2s,4as,6as,6br,8ar,10s,12as,12br,14br)-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-10-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-3,4,5,6,7,8,8a,10,11,12,12b,14b-dodecahydro-1h-picene-2-carboxylic acid

C36H56O9 (632.3924)

(1s,2r,6ar,6br,12ar)-1,2,6b,9,9,12a-hexamethyl-10-{[(3r,4s,5s,6r)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}-2,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydro-1h-picene-4a,6a-dicarboxylic acid

C36H56O9 (632.3924)

(4s)-4-[(2r,4ar,6r)-6-(5-bromo-2,6,6-trimethyloxan-2-yl)-4a,6,8a-trimethyl-tetrahydro-2h-pyrano[3,2-b]pyran-2-yl]-1-[(2r)-5-(2-hydroxypropan-2-yl)-2-methyloxolan-2-yl]pentane-1,4-diol

C32H57BrO7 (632.3287)

(1s,3r,6s,8r,12r,13r,15r,16r,18s)-15-[(2r)-4-[(2r)-3,3-dimethyloxiran-2-yl]-4-oxobutan-2-yl]-13,18-dihydroxy-7,7,12,16-tetramethyl-6-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}pentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadec-10-en-14-one

C35H52O10 (632.356)

(2s,3r,4s,5r)-2-[2-(6-chlorododecyl)-5-(7-chloroundecyl)-3-hydroxyphenoxy]oxane-3,4,5-triol

C34H58Cl2O6 (632.361)

(2r)-2-[(1r,3ar,4r,5ar,9as,11ar)-3a,6,6,9a,11a-pentamethyl-7-oxo-4-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,4h,5h,5ah,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl]-6-methylhept-5-enoic acid

C36H56O9 (632.3924)

(1r,2r,7r,10r,11s,14r,15s,16r)-16-[(2r)-4,5-dimethyl-6-oxo-2,3-dihydropyran-2-yl]-15-hydroxy-10,14,16-trimethyl-7-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-17-oxapentacyclo[13.2.2.0¹,¹⁴.0²,¹¹.0⁵,¹⁰]nonadec-4-en-9-one

C34H48O11 (632.3196)

6-{[3a-carboxy-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)-hexadecahydrocyclopenta[a]chrysen-9-yl]oxy}-3,4,5-trihydroxyoxane-2-carboxylic acid

C36H56O9 (632.3924)

(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl (4as,6as,6br,8ar,10s,11r,12ar,12br,14bs)-10,11-dihydroxy-1,2,6a,6b,9,9,12a-heptamethyl-4,5,6,7,8,8a,10,11,12,12b,13,14b-dodecahydro-3h-picene-4a-carboxylate

C36H56O9 (632.3924)

1,2,6b,9,9,12a-hexamethyl-10-[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy]-2,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydro-1h-picene-4a,6a-dicarboxylic acid

C36H56O9 (632.3924)

6,10,10,14,15,21,21-heptamethyl-9-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-3,24-dioxaheptacyclo[16.5.2.0¹,¹⁵.0²,⁴.0⁵,¹⁴.0⁶,¹¹.0¹⁸,²³]pentacosan-25-one

C36H56O9 (632.3924)

(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl (2r,4as,6as,6br,8ar,10r,11r,12ar,12br,14bs)-10,11-dihydroxy-2,6a,6b,9,9,12a-hexamethyl-1-methylidene-2,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydropicene-4a-carboxylate

C36H56O9 (632.3924)

(2s,3s,4s,5r,6r)-6-{[(3s,4ar,6ar,6bs,8as,12ar,14ar,14br)-8a-carboxy-4,4,6a,6b,11,11,14b-heptamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy}-3,4,5-trihydroxyoxane-2-carboxylic acid

C36H56O9 (632.3924)

(1s,2r,4as,6ar,6br,8ar,10s,12ar,12br,14bs)-1,2,6b,9,9,12a-hexamethyl-10-{[(2s,3s,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}-2,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydro-1h-picene-4a,6a-dicarboxylic acid

C36H56O9 (632.3924)

6-{[8a-carboxy-4-(hydroxymethyl)-4,6a,6b,14b-tetramethyl-11-methylidene-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicen-3-yl]oxy}-3,4,5-trihydroxyoxane-2-carboxylic acid

C35H52O10 (632.356)

(1s,3r,5r,6as,7s,8s,9r,10s,10as)-1,3-bis(acetyloxy)-7-[(2r)-2-hydroperoxy-3-methylidenepent-4-en-1-yl]-9,10-dihydroxy-7,8-dimethyl-1h,3h,5h,6h,6ah,8h,9h,10h-naphtho[1,8a-c]furan-5-yl (4e)-deca-2,4-dienoate

C34H48O11 (632.3196)

10-hydroxy-1,2,6b,9,9,12a-hexamethyl-4a-{[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy]carbonyl}-2,3,4,5,6,7,8,8a,10,11,12,12b,13,14b-tetradecahydro-1h-picene-6a-carboxylic acid

C36H56O9 (632.3924)

[(2r,3r,4s,5s,6r)-3,4-bis(acetyloxy)-5-hydroxy-6-{4-hydroxy-2-[(2e,6e,9s)-9-hydroxy-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]-5-methylphenoxy}oxan-2-yl]methyl acetate

C34H48O11 (632.3196)

2-(3a,6,6,9a,11a-pentamethyl-7-oxo-4-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,4h,5h,5ah,8h,9h,10h,11h-cyclopenta[a]phenanthren-1-yl)-6-methylhept-5-enoic acid

C36H56O9 (632.3924)

13-hydroxy-9-(3-hydroxybut-1-en-1-yl)-14-methyl-2-[(3,4,5-trimethoxy-6-methyloxan-2-yl)oxy]-1h,2h,3h,3ah,5ah,5bh,6h,9h,10h,11h,12h,13h,14h,16ah,16bh-as-indaceno[3,2-d]oxacyclododecane-7,15-dione

C35H52O10 (632.356)

2-{[6-hydroxy-1,4a,6-trimethyl-5-(3-methyl-3-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}pent-4-en-1-yl)-hexahydro-2h-naphthalen-1-yl]methoxy}-6-methyloxane-3,4,5-triol

C32H56O12 (632.3772)

15-[4-(3,3-dimethyloxiran-2-yl)-4-oxobutan-2-yl]-13,18-dihydroxy-7,7,12,16-tetramethyl-6-[(3,4,5-trihydroxyoxan-2-yl)oxy]pentacyclo[9.7.0.0¹,³.0³,⁸.0¹²,¹⁶]octadec-10-en-14-one

C35H52O10 (632.356)

13-hydroxy-6,14-diisopropyl-2,2,4,4,8,8,10,10-octamethyl-12-(2-methylpropanoyl)-6,14-dihydro-5,11-dioxapentaphene-1,3,7,9-tetrone

C38H48O8 (632.3349)

(1'r,2s,2's,4's,5s,7's,8'r,9's,12's,13'r,15'r,16'r,18's,19'r)-15',16',19'-tris(acetyloxy)-5,7',9',13'-tetramethyl-5'-oxaspiro[oxolane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-5-ylmethyl acetate

C35H52O10 (632.356)

(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl (4as,6as,6br,8ar,9r,10s,12ar,12br,14bs)-10-hydroxy-9-(hydroxymethyl)-1,2,6a,6b,9,12a-hexamethyl-4,5,6,7,8,8a,10,11,12,12b,13,14b-dodecahydro-3h-picene-4a-carboxylate

C36H56O9 (632.3924)

(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl (4as,6as,6br,8ar,10r,11r,12ar,12br,14bs)-10,11-dihydroxy-1,2,6a,6b,9,9,12a-heptamethyl-4,5,6,7,8,8a,10,11,12,12b,13,14b-dodecahydro-3h-picene-4a-carboxylate

C36H56O9 (632.3924)

(3r,5s)-3-[(1r,2s,3ar,5as,7s,9as,11as)-2-hydroxy-9a,11a-dimethyl-7-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,3ah,5h,5ah,6h,7h,8h,9h,11h-cyclopenta[a]phenanthren-1-yl]-5-[(2r,3s)-2-isopropyl-3-methyloxiran-2-yl]oxolan-2-one

C35H52O10 (632.356)

6a-({[3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy}methyl)-2,2,6b,9,9,12a-hexamethyl-10-oxo-3,4,5,6,7,8,8a,11,12,12b,13,14b-dodecahydro-1h-picene-4a-carboxylic acid

C39H52O7 (632.3713)

3-benzyl-9-{[4-(buta-2,3-dien-1-yloxy)-3-hydroxyphenyl]methyl}-5,11-dihydroxy-1,7-dimethyl-6,12-bis(2-methylpropyl)-1,4,7,10-tetraazacyclododeca-4,10-diene-2,8-dione

C36H48N4O6 (632.3574)

(2r,3as,5ar,5bs,9r,13s,14r,16as,16br)-13-hydroxy-9-[(1e,3s)-3-hydroxybut-1-en-1-yl]-14-methyl-2-{[(2r,3r,4r,5s,6s)-3,4,5-trimethoxy-6-methyloxan-2-yl]oxy}-1h,2h,3h,3ah,5ah,5bh,6h,9h,10h,11h,12h,13h,14h,16ah,16bh-as-indaceno[3,2-d]oxacyclododecane-7,15-dione

C35H52O10 (632.356)

methyl (1s,12r,14s,15e,18s)-12-[(1r,15s,17s,18s)-17-ethyl-7-methoxy-3,13-diazapentacyclo[13.3.1.0²,¹⁰.0⁴,⁹.0¹³,¹⁸]nonadeca-2(10),4,6,8-tetraen-6-yl]-15-ethylidene-10,17-diazatetracyclo[12.3.1.0³,¹¹.0⁴,⁹]octadeca-3(11),4,6,8-tetraene-18-carboxylate

C40H48N4O3 (632.3726)

(1r,4r,4ar,5s,6r,8s,8ar)-8-(acetyloxy)-8a-[(acetyloxy)methyl]-5,6-dimethyl-5-[(2s)-2-{[(2r)-2-methylbutanoyl]oxy}-2-(5-oxo-2h-furan-3-yl)ethyl]-hexahydro-2h-spiro[naphthalene-1,2'-oxiran]-4-yl (2e)-2-methylbut-2-enoate

C34H48O11 (632.3196)